TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two reviews found no clearly detectable increase in most measured adverse pregnancy outcomes after GLP-1 drug exposure around conception or early pregnancy. Researchers stressed that the evidence is limited and does not support taking the drugs during pregnancy; current advice to stop before planned conception remains in place.
Two reviews of pregnancy data found no clearly detectable increase in most measured adverse outcomes among women exposed to GLP-1 receptor agonists around conception or early pregnancy, but the researchers said the findings do not establish that the drugs are safe during pregnancy. The results may offer limited reassurance after inadvertent exposure, while current recommendations to stop treatment before planned conception remain unchanged.
A systematic review and meta-analysis of 10 studies covering more than 2.1 million pregnancies, reported in the journal Med, found no clear increase in miscarriage or intrauterine death, congenital anomalies, preterm birth, hypertensive disorders, gestational diabetes, altered fetal growth, or excess gestational weight gain among women who used GLP-1 drugs in the periconceptional period compared with those who did not. The authors said analyses grouped by reason for treatment were consistent with the main results.
The pooled estimate for preeclampsia was lower among exposed women (odds ratio 0.87, 95% confidence interval 0.78 to 0.98), but it came from just two datasets. Asma Khalil, MD, MSc, of City St George’s University of London, and colleagues cautioned that this result should be interpreted carefully. They cited differences in how exposure was defined, possible residual confounding and the small number of studies for several outcomes as limits on the evidence.
A second review, presented at the European Association for the Study of Diabetes annual meeting and published in Lancet Obstetrics, Gynaecology & Women’s Health, examined data on more than 40,000 women, primarily with type 2 diabetes. Across four studies, it found no increase in congenital anomaly risk when GLP-1 drugs were discontinued during the first trimester (risk ratio 1.02, 95% CI 0.96 to 1.08). Early pregnancy loss was more common in exposed women in two studies (RR 1.31, 95% CI 1.26 to 1.35), but the researchers said interpretation was difficult because the largest study combined miscarriage and termination.
Guidance Remains Cautious
The reviews examined pregnancy outcomes after GLP-1 drug exposure near conception, a period when some people may not yet know they are pregnant. They provide evidence about reported outcomes after such exposure, but neither determines whether continued use during pregnancy is safe. The findings do not change recommendations to discuss treatment with a clinician before trying to conceive.
GLP-1 receptor agonists are not approved for use during pregnancy. Drug labeling recommends stopping them at least two months before planned conception, although the source report says that guidance draws on limited human data. Claire Meek, PhD, of the University of Leicester, said the new consensus guidance aims to help clinicians identify treatment targets before conception and help women understand when and how to stop treatment safely.
What the Reviews Examined
The first review combined studies of women with exposure in the period around conception, comparing their pregnancy outcomes with those of women without reported exposure. A separate review focused on data largely involving women with type 2 diabetes and assessed outcomes including congenital anomalies and early pregnancy loss. These reviews provide observational evidence from past pregnancies; they are not trials that assign treatment during pregnancy.
Tricia Tan, MBChB, PhD, of Imperial College London, told the U.K.’s Science Media Centre that the studies found no detectable serious problem across pregnancy outcomes. She also said studies of past practice may not reflect current practice. The authors of the second review developed an international consensus statement on GLP-1 use before, during and after pregnancy in women with diabetes, according to the source report.
“The results “may provide limited reassurance following inadvertent exposure before conception or during early pregnancy, but they should not be interpreted as supporting continued treatment during pregnancy.””
— Asma Khalil and colleagues
Limits of Pregnancy Evidence
The reviews do not establish whether GLP-1 drugs are safe to take during pregnancy. Their findings are constrained by observational data, differences in exposure definitions and potential confounding. Several outcomes drew on only a small number of studies, and the early-loss result cannot distinguish miscarriage from termination in the largest contributing dataset.
Evidence is also scarce for use in people with type 1 diabetes, gestational diabetes and during lactation, according to the source report. Meek said there is substantial interest among women with type 1 diabetes but “almost no evidence.” The review findings do not resolve these gaps or settle the benefits and risks of treatment in those groups.
More Data and Clinical Guidance
For now, the reported recommendation is to stop GLP-1 treatment before planned conception; if pregnancy occurs, Meek said treatment should stop in early pregnancy. People taking these drugs who are planning a pregnancy or discover they are pregnant should discuss the medication with their healthcare professional, who can advise on stopping treatment and managing the underlying condition.
The consensus authors called for more investment in women’s health research, regulatory changes that allow evidence to be gathered while protecting women and unborn children, and mandatory reporting of data by sex. Further studies will be needed to clarify outcomes across different drugs, treatment indications and pregnancy stages, as well as use during lactation.
Key Questions
Do these studies show that GLP-1 drugs are safe during pregnancy?
No. They found no clear increase in most measured adverse outcomes, but the authors said the evidence is limited and does not establish safety during pregnancy.
What should someone do if they become pregnant while taking a GLP-1 drug?
Meek said treatment should stop in early pregnancy. The person should contact their healthcare professional for advice on the medication and care for the condition being treated.
How long before a planned pregnancy should GLP-1 drugs be stopped?
Drug labeling recommends stopping at least two months before planned conception. The source report says this guidance relies on limited human data.
What did the second review find about early pregnancy loss?
It reported a higher pooled estimate for early pregnancy loss among exposed women in two studies. The researchers said the finding is difficult to interpret because miscarriage and termination were combined in the largest contributing study.
Is there enough evidence about GLP-1 drugs and breastfeeding?
No. The source report describes lactation data as scarce. The consensus authors advised using the lowest effective dose for women taking GLP-1 drugs while breastfeeding.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
